Scientific Reports
October 11, 2023
Sven Wasserthal, Mirko Lehmann, Claudia Neumann et al.
7 citations
Schizophrenia is associated with various deficits in social cognition that remain relatively unaltered by antipsychotic treatment. While faulty glutamate signaling has been associated with general cognitive deficits as well as negative symptoms of schizophrenia, no direct link between manipulation of glutamate signaling and deficits in mentalizing has been demonstrated thus far. Here, we...
Schizophrenia
May 12, 2021
Musa Basseer Sami, Luciano Annibale, Aisling O’neill et al.
5 citations
Abstract It is unclear whether early psychosis in the context of cannabis use is different from psychosis without cannabis. We investigated this issue by examining whether abnormalities in oculomotor control differ between patients with psychosis with and without a history of cannabis use. We studied four groups: patients in the early phase of psychosis with a history of cannabis use (EPC; n =...
Neuroscience of Consciousness
2021
Mirko Lehmann, Claudia Neumann, Sven Wasserthal et al.
Only little research has been conducted on the pharmacological underpinnings of metacognition. Here, we tested the modulatory effects of a single intravenous dose (100 ng/ml) of the N-methyl-D-aspartate-glutamate-receptor antagonist ketamine, a compound known to induce altered states of consciousness, on metacognition and its neural correlates. Fifty-three young, healthy adults completed two...
Schizophrenia Bulletin Open
2020
Musa Sami, Robert A. McCutcheon, Ulrich Ettinger et al.
Both chronic cannabis use and psychotic disorders are associated with abnormalities in visual attentional processing. Using functional magnetic resonance imaging (fMRI), we sought to determine whether there would be a difference in functional connectivity in patients and controls with and without a history of cannabis use in the visual and dorsal attention networks. Resting-state fMRI data were...
Psychopharmacology
December 2018
M Steffens, Claudia Neumann, A-M Kasparbauer et al.
The uncompetitive N-methyl-D-aspartate (NMDA) receptor (NMDAR) antagonist ketamine has been proposed to model symptoms of psychosis. Inhibitory deficits in the schizophrenia spectrum have been reliably reported using the antisaccade task. Interestingly, although similar antisaccade deficits have been reported following ketamine in non-human primates, ketamine-induced deficits have not been...
Consciousness and Cognition
February 2017
Veena Kumari, Elena Antonova, Bernice Wright et al.
This study examined the effects of cultivated (i.e. developed through training) and dispositional (trait) mindfulness on smooth pursuit (SPEM) and antisaccade (AS) tasks known to engage the fronto-parietal network implicated in attentional and motion detection processes, and the fronto-striatal network implicated in cognitive control, respectively. Sixty healthy men (19-59years), of whom 30...
Schizophrenia Research: Cognition
September 2016
Elena Antonova, Kavitha Amaratunga, Bernice Wright et al.
Despite growing evidence for demonstrated efficacy of mindfulness in various disorders, there is a continuous concern about the relationship between mindfulness practice and psychosis. As schizotypy is part of the psychosis spectrum, we examined the relationship between long-term mindfulness practice and schizotypy in two independent studies. Study 1 included 24 experienced mindfulness...
Translational Psychiatry
December 1, 2013
Anne Schmechtig, J. Lees, A. Perkins et al.
The non-competitive N-methyl-D-aspartate receptor antagonist ketamine leads to transient psychosis-like symptoms and impairments in oculomotor performance in healthy volunteers. This study examined whether the adverse effects of ketamine on oculomotor performance can be reversed by the atypical antipsychotic risperidone. In this randomized double-blind, placebo-controlled study, 72 healthy...